Supriya Lifescience Limited (BOM:543434)
863.35
+26.65 (3.19%)
At close: Jul 21, 2026
Supriya Lifescience Revenue
In the fiscal year ending March 31, 2026, Supriya Lifescience had annual revenue of 8.28B INR with 18.86% growth. Supriya Lifescience had revenue of 2.77B in the quarter ending March 31, 2026, with 50.20% growth.
Revenue
8.28B
Revenue Growth
+18.86%
P/S Ratio
8.17
Revenue / Employee
16.08M
Employees
515
Market Cap
67.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.28B | 1.31B | 18.86% |
| Mar 31, 2025 | 6.96B | 1.26B | 22.12% |
| Mar 31, 2024 | 5.70B | 1.09B | 23.73% |
| Mar 31, 2023 | 4.61B | -691.11M | -13.04% |
| Mar 31, 2022 | 5.30B | 1.39B | 35.49% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viyash Scientific | 34.20B |
| Unichem Laboratories | 22.02B |
| FDC Limited | 21.71B |
| Morepen Laboratories | 18.06B |
| Sanofi India | 17.74B |
| Procter & Gamble Health | 14.08B |
| CORONA Remedies | 14.03B |
| Gufic Biosciences | 9.44B |